Floatz logo

Nogitecan

Childhood Medulloblastoma

Explore 2 assets in Childhood Medulloblastoma →
Floatz Rating
BB64/100
Confidence
Indicative
v0.2
Sponsor
City of Hope Medical Center
Modality
Small molecule
Development Phase
Phase 2
Status
Dormant
Evidence ledger · v0.2

Clinical Evidence

Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
49High confidence
Detailed axis rationale is planned and will be published soon.

No trial-level evidence is linked to this axis yet.

Competitive Position

Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
95High confidence
Detailed axis rationale is planned and will be published soon.

Same indication · Childhood Medulloblastoma

AssetSponsorPhaseRating
Nogitecan (this asset)City of Hope Medical CenterP2BB · 64
NivestimMayo ClinicP3BB
IrinotecanNational Cancer Institute (NCI)P2BB
2 (1H))-QUINOLINONE,6-(AMINO(4-CHLOROPHENYL)(1-METHYL-1H-IMIDAZOL-5-YL)METHYL)-4-(3-CHLOROPHENYL)-1-METHYL-,(+)-National Cancer Institute (NCI)P2B
EdotreotideSue O'DorisioP2CCC
Pan-Fgfr Tyrosine Kinase Inhibitor Jnj-42756493National Cancer Institute (NCI)P2CCC
VorinostatNational Cancer Institute (NCI)P1CCC
RomidepsinCity of Hope Medical CenterP1CCC
DexasoneNational Cancer Institute (NCI)P1CCC

+18 more in the Childhood Medulloblastoma cohort

Other indications for Nogitecan

IndicationSponsorPhaseRating
Primary Peritoneal Carcinoma—P3BBB · 74
Cancer Of Unknown Primary Site—P2BBB · 72
Non-Small Cell Lung Carcinoma—P3BBB · 72

Scientific Foundation

Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR

Planned for methodology v0.2.

Development Feasibility

How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR

Planned for methodology v0.2.

Commercial Opportunity

Commercial prize: addressable population, unmet need, and the value case for the indication.
NR

Planned for methodology v0.2.

IP & Exclusivity

Exclusivity position, covering patent protection and freedom-to-operate runway.
NR

Planned for methodology v0.2.

Manufacturing & Supply

Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR

Planned for methodology v0.2.

Related assets

Citation

Floatz Terminal. Nogitecan in Childhood Medulloblastoma. Methodology v0.2.
Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026.
Accessed July 14, 2026.
https://terminal.floatz.ai/assets/nogitecan-childhood-medulloblastoma

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →